Key facts
- Arialys Therapeutics’s last known valuation is $112.0M (Jun 2025).
- It has raised $72.0M across 2 recorded rounds; the latest was Early Stage VC ($14.8M) in Jun 2025.
- Notable investors include Alexandria Venture Investments, Johnson & Johnson JJDC, MPM BioImpact, Alexandria Real Estate Equities, Avalon Bioventures — 6 tracked in total.
- Arialys Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Jul 2025 ($14.8M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Arialys Therapeutics
Funding rounds
2 roundsAbout Arialys Therapeutics
Operator of a clinical-stage biotechnology company intended to pioneer new precision medicines for autoimmune neuropsychiatric diseases. The company specializes in the field of neuroscience and characterizes the nature and prevalence of pathogenic auto-antibody activity in the central nervous system converged network services, enabling clients to avail advanced breakthrough therapies for a variety of central nervous system disorders and treating neuropsychiatric disorders driven by autoimmune diseases.
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2021
- Employees
- 10
- Website
- arialysrx.com/
- Ownership
- Privately Held (backing)
Arialys Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arialys Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arialys Therapeutics in its N-PORT filings yet. We sweep new filings monthly.